A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors
Clinical trial NCT05144061 · COMPLETED
Trial details
- NCT number
- NCT05144061
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-20
- Primary completion
- 2024-02-21
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.